Dr. Daniel Petrylak on the IMvigor Study of Atezolizumab in Advanced Bladder Cancer
Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the IMvigor Study, which looked at anti PD-1 agent atezolizumab in advanced urothelial carcinoma.
Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the IMvigor Study, which looked at anti PD-1 agent atezolizumab in advanced urothelial carcinoma.
The study evaluated atezolizumab given every three weeks at 1,200 mg. It also investigated the role of PD-L1 expression in the tumor immune cells, says Petrylak. It was determined that there was a better response rate in patients who were strong expressers of PD-L1 in the immune cells.
Previous trials have shown that there is no correlation between tumor cell expression of PD-L1 and outcome with anti PD-1 agents, explains Petrylak. However, when looking at just the immune cells, a positive relationship between PD-L1 expression and improved outcome with anti PD-1 agents was found.
Updated Trials at ESMO Reveal New Frontline Combo in Urothelial Carcinoma
December 2nd 2023Findings presented during the 2023 ESMO Annual Meeting have demonstrated a new combination of targeted therapies offering clinicians and patients renewed hope in this difficult to treat cancer type.
Read More
